Epidemiology and Public Health
The broad purpose of the Epidemiology and Public Health research group is contributing to increase the available scientific evidence regarding preventive interventions, to promote health, and prevent morbidity and mortality from major diseases. Our group uses epidemiological methods to study etiology, surveillance, and efficacy of these interventions. We are primarily focused on epidemiology and prevention of infectious diseases, in both individual and population levels.
Main lines of research:
- Vaccines: This research line includes the organization, participation and collaboration in different clinical trials related to the evaluation of the immunogenicity, efficacy and safety of different vaccines (e.g. Herpes Zoster, Respiratory Syncytial Virus, Influenza, Covid-19).
- The epidemiology and prevention of healthcare acquired infections: This research line includes the evaluation of risk factors, characteristics, evolution, host, and impact of these infections.
- Clinical Epidemiology of Multiple Sclerosis: The objective of this project is to characterize the epidemiology of Multiple Sclerosis in Catalonia.
Publications
Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
PMID: 35192034
Journal: JOURNAL OF NEUROLOGY
Year: 2022
Reference: J Neurol. 2022 Apr;269(4):1773. doi: 10.1007/s00415-022-11019-9.
Impact factor:
Publication type: Letter or abstract
Authors: Arrambide, Georgina; Auger, Cristina; Carbonell, Pere; Cardenas-Robledo, Simon; Castillo, Joaquin; Castillo, Mireia; Cobo-Calvo, Alvaro; Comabella, Manuel; Espejo, Carmen; Galan, Ingrid et al.
DOI: 10.1007/s00415-022-11019-9
Brand-Specific Enhanced Safety Surveillance Study of GSK's Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season.
PMID: 34961900
Journal: Infectious Diseases and Therapy
Year: 2022
Reference: Infect Dis Ther. 2022 Feb;11(1):463-483. doi: 10.1007/s40121-021-00571-y. Epub 2021 Dec 27.
Impact factor:
Publication type: Paper in international publication
Authors: Dos Santos, Gael; Eckermann, Tamara; Godard, Eric; Godderis, Lode; Jindal, Pooja; Martinez Gomez, Xavier; Nwoji, Ugo; Pallem, Sridevi; Roul, Helene; Rybo, Maria et al.
DOI: 10.1007/s40121-021-00571-y
Reconciling short-term clinical and Immunological outcomes of SARS-CoV-2 vaccination in Solid Organ Transplant recipients.
PMID: 34554648
Journal: AMERICAN JOURNAL OF TRANSPLANTATION
Year: 2022
Reference: Am J Transplant. 2022 Feb;22(2):673-675. doi: 10.1111/ajt.16855. Epub 2021 Oct 5.
Impact factor:
Publication type: Letter or abstract
Authors: Bestard, Oriol; Campins, Magda; Campos-Varela, Isabel; Castells, Lluis; Crespo, Elena; Esperalba, Juliana; Jouve, Thomas; Len, Oscar; Lopez, Manuel; Moreso, Francesc et al.
DOI: 10.1111/ajt.16855
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.
PMID: 35105687
Journal: Neurology-Neuroimmunology & Neuroinflammation
Year: 2022
Reference: Neurol Neuroimmunol Neuroinflamm. 2022 Feb 1;9(2). pii: 9/2/e1143. doi: 10.1212/NXI.0000000000001143. Print 2022 Mar.
Impact factor:
Publication type: Paper in international publication
Authors: Arrambide, Georgina; Beltran, Jordina; Bonastre, Merce; Carbonell-Mirabent, Pere; Cardenas-Robledo, Simon; Castillo, Joaquin; Castillo, Mireia; Cobo-Calvo, Alvaro; Comabella, Manuel; Espejo, Carmen et al.
DOI: 10.1212/NXI.0000000000001143
Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials.
PMID: 33328323
Journal: NEUROLOGY
Year: 2021
Reference: Neurology. 2021 Jan 26;96(4):e482-e490. doi: 10.1212/WNL.0000000000011339. Epub 2020 Dec 16.
Impact factor:
Publication type: Paper in international publication
Authors: Arrambide, Georgina; Auger, Cristina; Cabello, Sergio; Castillo, Joaquin; Comabella, Manuel; Galan, Ingrid; Midaglia, Luciana; Moncho, Dulce; Montalban, Xavier; Nos, Carlos et al.
DOI: 10.1212/WNL.0000000000011339
[Characteristics of patients with invasive pneumococcal disease requiring admission to intensive care units].
PMID: 32998844
Journal: ANALES DE PEDIATRIA
Year: 2021
Reference: An Pediatr (Barc). 2021 Jan;94(1):19-27. doi: 10.1016/j.anpedi.2020.03.013. Epub 2020 Sep 29.
Impact factor:
Publication type: Paper in national publication
Authors: Campins, Magda; Ciruela, Pilar; Codina, Gemma; de Sevilla, Mariona Fernandez; Diaz-Conradi, Alvaro; Dominguez, Angela; Dominguez, Angela; Esteva, Cristina; Fernandez de Sevilla, Mariona; Garcia-Garcia, Juan Jose et al.
DOI: 10.1016/j.anpedi.2020.03.013
Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement.
PMID: 32561334
Journal: NEUROLOGIA
Year: 2021
Reference: Neurologia. 2021 Jan - Feb;36(1):50-60. doi: 10.1016/j.nrl.2020.02.006. Epub 2020 Jun 17.
Impact factor:
Publication type: Paper in national publication
Authors: Ara, J R; Blanco, Y; Brieva, L; Calles, C; Carmona, O; Casanova, V; Costa-Frossard, L; Eichau, S; Garcia-Merino, J A; Garcia-Vidal, C et al.
DOI: 10.1016/j.nrl.2020.02.006
Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection.
PMID: 34960209
Journal: Vaccines
Year: 2021
Reference: Vaccines (Basel). 2021 Dec 10;9(12). pii: vaccines9121463. doi: 10.3390/vaccines9121463.
Impact factor: 4.422
Publication type: Paper in international publication
Authors: Pares-Badell, Oleguer, Martinez-Gomez, Xavier, Pinos, Laia, Borras-Bermejo, Blanca, Uriona, Sonia, Otero-Romero, Susana, Rodrigo-Pendas, Jose Angel, Cossio-Gil, Yolima, Agusti, Antonia, Aguilera, Cristina et al.
DOI: 10.3390/vaccines9121463
News
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.
L’Agència Europea de Medicaments autoritza la vacuna d'HIPRA contra la COVID-19 com a dosi de reforç
El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.